Spectrum of Bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy

被引:133
|
作者
Gonzalez, OY
Musher, DM
Brar, I
Furgeson, S
Boktour, MR
Septimus, EJ
Hamill, RJ
Graviss, EA
机构
[1] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA
[3] Vet Affairs Med Ctr, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Texas, Hlth Sci Ctr, Houston, TX USA
[6] Memorial Hermann Hlth Care Syst, Houston, TX USA
[7] Henry Ford Hosp, Detroit, MI USA
关键词
D O I
10.1086/344908
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Intravesical instillation of bacille Calmette-Guerin (BCG) effectively treats transitional cell carcinoma of the bladder. Occasionally, BCG infection complicates such treatment. In some patients, infection appears early (within 3 months after instillation) and is characterized by generalized symptoms, with pneumonitis and hepatitis. Late-presentation disease occurs >1 year after the first BCG treatment and usually involves focal infection of the genitourinary tract (the site at which bacteria were introduced) and/or other sites that are typical for reactivation of mycobacterial disease, such as the vertebral spine or the retroperitoneal tissues. Noncaseating granulomas are found in the majority of cases, whether early or late. Most patients respond to treatment with antituberculous drugs; in early-presentation disease, when features of hypersensitivity predominate, glucocorticosteroids are sometimes added. Late localized infection often requires surgical resection.
引用
收藏
页码:140 / 148
页数:9
相关论文
共 50 条
  • [1] Major adverse reactions after intravesical Bacille Calmette-Guerin (BCG) immunotherapy
    Yaguee Hernando, A.
    Guarch Troyas, R.
    Echegoyen Silanes, A.
    Lopez, J. I.
    Marta Casanova, C. B.
    Garcia Guevara, K. S.
    Garcia Garcia, D.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 346 - 347
  • [2] Bone marrow infection with bacillus Calmette-Guerin (BCG) after intravesical immunotherapy
    Nemeth, Johannes
    Stoiser, Brigitte
    Winkler, Heide-Maria
    Muellauer, Leonard
    Graninger, Wolfgang
    Winkler, Stefan
    WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 (3-4) : 121 - 123
  • [3] Intravesical Bacille Calmette-Guerin (BCG) Vaccine Affects Cognition
    Greenblatt, Charles L.
    Bercovier, Herve
    Klein, Benjamin Y.
    Gofrit, Ofer N.
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 100 (03) : 771 - 774
  • [4] RENAL TUBERCULOSIS AFTER INTRAVESCIAL BACILLE CALMETTE-GUERIN (BCG) IMMUNOTHERAPY
    Han, T.
    Han, C.
    Thet, Z.
    NEPHROLOGY, 2017, 22 : 73 - 73
  • [5] Non-specific immunotherapy with bacille Calmette-Guerin (BCG)
    van der Meijden, APM
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 123 (02): : 179 - 180
  • [6] AERODIGESTIVE TRACT PAPILLOMATOSIS - BACILLE CALMETTE-GUERIN (BCG) IMMUNOTHERAPY
    STRAUSS, M
    CONNER, GH
    HARVEY, HA
    WHITE, DS
    LARYNGOSCOPE, 1982, 92 (09): : 971 - 975
  • [7] Intravesical immunotherapy/bacille Calmette-Guerin
    Chopin, D
    Saint, F
    Gattegno, B
    PROGRES EN UROLOGIE, 2001, 11 (05): : 1065 - 1115
  • [8] Tuberculous Orchitis Following Intravesical Bacille Calmette-Guerin (BCG) Therapy
    Klebanov, Nikolai
    Raghavan, Aravind
    CUREUS, 2018, 10 (05):
  • [10] Bacille Calmette-Guerin (BCG) vaccination in Canada
    Behr, Marcel
    Elwood, Kevin
    CANADIAN RESPIRATORY JOURNAL, 2013, 20 : 152A - 155A